A number of adverse events considered by the investigator to be related to motesanib treatment that were of specific interest occurred, including events that are considered class effects of VEGF(R) treatment [21], such as hypertension, thromboembolic events, hemorrhagic events, and neutropenia (Table 2). The gene discussed is VEGFA; the disease is neutropenia.